Latest period
$31.4B
YoY change
+53.2%
5Y CAGR
+78.0%
Peak year (FY2025)
$30.5B
Latest annual
$30.5B
Total Equity history chart for Novo Nordisk (NVO) from 2016 to 2025
Latest: $30.5B
Total Equity growth chart for Novo Nordisk (NVO) from 2016 to 2025
Latest: +53.2%
Total Equity history table for Novo Nordisk (NVO) from 2003 to 2025
| FY2025 | $30.5B | +53.2% | +$10.6B | ||
| FY2024 | $19.9B | +26.3% | +$4.14B | ||
| FY2023 | $15.8B | +31.3% | +$3.76B | ||
| FY2022 | $12B | +11.1% | +$1.2B | ||
| FY2021 | $10.8B | +533.2% | +$9.11B | ||
| FY2020 | $1.71B | +31.6% | +$411M | ||
| FY2019 | $1.3B | -83.7% | -$6.66B | ||
| FY2018 | $7.96B | -0.8% | -$67.7M | ||
| FY2017 | $8.03B | +25.3% | +$1.62B | ||
| FY2016 | $6.41B | -6.4% | -$435M | ||
| FY2015 | $6.84B | +4.5% | +$293M | ||
| FY2014 | $6.55B | -16.8% | -$1.32B | ||
| FY2013 | $7.87B | +9.5% | +$681M | ||
| FY2012 | $7.19B | +10.1% | +$657M | ||
| FY2011 | $6.53B | -1.6% | -$107M | ||
| FY2010 | $6.64B | -3.5% | -$241M | ||
| FY2009 | $6.88B | +10.8% | +$673M | ||
| FY2008 | $6.21B | -1.6% | -$104M | ||
| FY2007 | $6.31B | +18.3% | +$977M | ||
| FY2006 | $5.33B | +21.7% | +$951M | ||
| FY2005 | $4.38B | -10.0% | -$487M | ||
| FY2004 | $4.87B | +13.8% | +$591M | ||
| FY2003 | $4.28B | — | — | ||
| FY2002 | — | — | — | ||
| FY2001 | — | — | — | ||
| FY2000 | — | — | — | ||
| FY1999 | — | — | — | ||
| FY1998 | — | — | — | ||
| FY1997 | — | — | — | ||
| FY1996 | — | — | — | ||
| FY1995 | — | — | — | ||
| FY1994 | — | — | — | ||
| FY1993 | — | — | — | ||
| FY1992 | — | — | — | ||
| FY1991 | — | — | — | ||
| FY1990 | — | — | — | ||
| FY1989 | — | — | — | ||
| FY1988 | — | — | — | ||
| FY1987 | — | — | — | ||
| FY1986 | — | — | — | ||
| FY1985 | — | — | — |
- FY2025$30.5B+53.2%
- FY2024$19.9B+26.3%
- FY2023$15.8B+31.3%
- FY2022$12B+11.1%
- FY2021$10.8B+533.2%
- FY2020$1.71B+31.6%
- FY2019$1.3B-83.7%
- FY2018$7.96B-0.8%
- FY2017$8.03B+25.3%
- FY2016$6.41B-6.4%
- FY2015$6.84B+4.5%
- FY2014$6.55B-16.8%
- FY2013$7.87B+9.5%
- FY2012$7.19B+10.1%
- FY2011$6.53B-1.6%
- FY2010$6.64B-3.5%
- FY2009$6.88B+10.8%
- FY2008$6.21B-1.6%
- FY2007$6.31B+18.3%
- FY2006$5.33B+21.7%
- FY2005$4.38B-10.0%
- FY2004$4.87B+13.8%
- FY2003$4.28B—
- FY2002——
- FY2001——
- FY2000——
- FY1999——
- FY1998——
- FY1997——
- FY1996——
- FY1995——
- FY1994——
- FY1993——
- FY1992——
- FY1991——
- FY1990——
- FY1989——
- FY1988——
- FY1987——
- FY1986——
- FY1985——
Total Equity values are taken from Novo Nordisk's reported balance sheets (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts converted to USD using IAS 21 average exchange rates (P&L / cash flow) or closing rates (balance sheet). Originally filed in DKK.
About Total Equity at Novo Nordisk (NVO)
According to Novo Nordisk's latest reported financial statements, the company's latest reported total equity is $31.4B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Novo Nordisk (NVO) total equity totalled 194B DKK – surged 35.2% year-over-year.
Novo Nordisk total equity has grown for 6 consecutive years, with a +79.5% compound annual growth rate over 2020–2025 (5 years).
2025 marks the peak total equity at 194B DKK, with the historical low of 4.07B DKK recorded in 1986.
Novo Nordisk Total Equity by Year
Novo Nordisk Total Equity 2025: $30.5B
2025's total equity for Novo Nordisk came in at 194B DKK ($30.5B), surged 35.2% from 2024. This figure represents the highest annual value in the available history.
Novo Nordisk Total Equity 2024: $19.9B
Novo Nordisk posted total equity of 143B DKK ($19.9B) in 2024, surged 34.7% from 2023.
Novo Nordisk Total Equity 2023: $15.8B
In 2023, Novo Nordisk reported total equity of 107B DKK ($15.8B), grew 27.6% from 2022.
Novo Nordisk Total Equity 2022: $12B
Novo Nordisk total equity in 2022 was 83.5B DKK ($12B), grew 18.0% from 2021.
Novo Nordisk Total Equity 2021: $10.8B
Novo Nordisk total equity in 2021 was 70.7B DKK ($10.8B).
See more financial history for Novo Nordisk (NVO).
Sector peers by Total Equity
Healthcare peers of Novo Nordisk (NVO), ranked by their latest total equity
| $94.1B | |
| $81.5B | |
| $53.4B | |
| $52.6B | |
| $52.1B | |
| $26.5B | |
| $8.66B | |
| -$3.27B |
- $94.1B
- $81.5B
- $52.6B
- $26.5B
- $8.66B
- -$3.27B
Frequently asked questions
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks0.23% TTM
- Dividend Profile3.74% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History5 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.